Toxic Erythema of Chemotherapy, Vasculitic Eruption With Malignant Intertrigo Characteristics, and Superimposed Infection Post-bevacizumab Initiation.
Document Type
Article
Publication Date
1-23-2024
Publication Title
Cureus
Abstract
Drug reactions are a known risk in combined anti-cancer therapy. Less commonly recognized risks of chemotherapies and targeted immunotherapies include toxic erythema of chemotherapy reactions. With the immunosuppressive quality of cancer combined with anti-cancer treatments, patients are also susceptible to increased infection. We report a rare case of combined targeted anti-cancer treatment with bevacizumab and lorlatinib, and an associated transformation of an eczematous process into a toxic erythema of chemotherapy vasculitic eruption, with combined malignant intertrigo characteristics and superimposed infection following the initiation of bevacizumab.
Volume
16
Issue
1
First Page
e52816
Last Page
e52816
Recommended Citation
Slater KN, Nessel T, Kartono F. Toxic erythema of chemotherapy, vasculitic eruption with malignant intertrigo characteristics, and superimposed infection post-bevacizumab initiation. Cureus. 2024 Jan 23;16(1):e52816. doi: 10.7759/cureus.52816. PMID: 38406049; PMCID: PMC10884723.
DOI
10.7759/cureus.52816
ISSN
2168-8184
PubMed ID
38406049
